Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynavax names new CEO

This article was originally published in Scrip

Executive Summary

Dynavax Technologies, a biopharmaceutical company developing products to prevent and treat infectious and inflammatory diseases, has appointed Eddie Gray chief executive officer and a member of its board of directors, effective 1 May 2013. Before joining Berkeley, California-based Dynavax, Mr Gray served as president of pharmaceuticals Europe at big pharma GlaxoSmithKline. He succeeds Dr Dino Dina as CEO of the Dynavax. Dr Dina will remain a consultant to the firm for the transitional period and plans to continue to serve on the company's board. Additionally, Dr Tyler Martin, president, is departing from Dynavax on 31 May 2013.

You may also be interested in...



Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Execs On The Move, Oct 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Related Companies

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel